DBV Technologies: net loss widens in Q1
The biopharmaceutical company, which specializes in food allergies, adds that its operating revenues decreased to $1.4 million, compared with $2.2 million at the end of March 2023, due to the termination of the contract with Nestlé Health Science in October 2023.
Cash and cash equivalents stood at $101.5 million at the end of March 2024, a net decrease of $39.9 million over three months, mainly due to operational activities, including patient recruitment for the VITESSE trial.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction